State of the Art Remodeling in Asthma Ce´line Bergeron1, Wisam Al-Ramli2, and Qutayba Hamid2 1 2
Hotel-Dieu Hospital, Centre Hospitalier de l’Universite´ de Montre´al, University of Montreal, Montre´al, Quebec, Canada; and Meakins-Christie Laboratories, McGilll University, Health Centre Research Institute, Montre´al, Canada
Airway remodeling refers to the structural changes that occur in both the large and the small airways of miscellaneous diseases, including asthma. In asthma, airway structural changes include subepithelial fibrosis, increased smooth muscle mass, enlargement of glands, neovascularization, and epithelial alterations. Although controversial, airway remodeling is commonly attributed to the underlying chronic inflammatory process. These remodeling changes contribute to thickening of airway walls and consequently lead to airway narrowing, bronchial hyperresponsiveness, airway edema, and mucous hypersecretion. Airway remodeling is associated with poorer clinical outcome among patients with asthma. Early diagnosis and prevention of airway remodeling has the potential to decrease disease severity, to improve control, and to prevent disease expression. In this article, we briefly provide an update on the characteristic features of airway remodeling observed in asthma and their clinical consequences.
process of epithelial shedding is currently controversial and still a matter of debate, as some propose the detachment to be simply an artifact of physical tissue sampling of the asthmatic airways (20, 21). Studies suggest that either the asthmatic epithelium has a weakened attachment to the basement membrane or that asthmatic epithelial cells have a higher turnover compared with epithelial cells from healthy control subjects. Clinically, the extent of epithelial injury is correlated to airway hyperresponsiveness (17, 22), clearly suggesting that the degree of epithelial loss and/or turnover is related to asthma development and severity. The intact airway epithelium normally provides a physical protective barrier against inhaled small particles such as allergens. The loss of epithelium surface and the resultant denudation of the basement membrane may decrease this protective effect and increase the propensity for allergic insult on the airway.
Keywords: remodeling; asthma; inflammation
Airway remodeling in asthma was first described in 1922 by Hubert and Koessler in cases of fatal asthma (reviewed in Reference 1). Airway remodeling has been documented in all degrees of asthma severities and in both large and small airways (2). Airway remodeling refers to structural changes in airways of subjects with asthma which are not seen in healthy subjects. Figure 1 summarizes airway remodeling features. Structural changes include loss of epithelial integrity (3), thickening of basement membrane (4), subepithelial fibrosis (5), goblet cell and submucosal gland enlargement (6, 7), increased smooth muscle mass (6), decreased cartilage integrity (8), and increased airway vascularity (9, 10). Figure 2 shows remodeling features in asthma. It is believed that these changes largely stem from an ongoing chronic inflammatory process that involves activation of inflammatory cells including CD41 T cells, eosinophils, neutrophils, and mast cells (11–15). Duration of asthma has been associated with reduced lung function, increased hyperresponsiveness and asthma symptoms, as well as greater use of medication (5, 16, 17), and the remodeling process has been proposed to explain these features.
EPITHELIAL ALTERATION Epithelial alterations in asthma include epithelial shedding, loss of ciliated cells, goblet cell hyperplasia, up-regulation of growthfactor release, and the overexpression of receptors, such as epidermal growth factor receptors (EGFR) (3, 6, 18–20). The
(Received in original form August 19, 2008; accepted in final form February 27, 2009) Correspondence and requests for reprints should be addressed to Qutayba Hamid, M.D., Ph.D., Meakins-Christie Laboratories, McGill University, 3626 St Urbain Street, Montre´al, PQ, H2X 2P2 Canada. E-mail:
[email protected] Proc Am Thorac Soc Vol 6. pp 301–305, 2009 DOI: 10.1513/pats.200808-089RM Internet address: www.atsjournals.org
SUBEPITHELIAL FIBROSIS A second important feature of airway remodeling is the subepithelial fibrosis. Since it was first observed in 1922 (reviewed in Reference 1) in cases of fatal asthma, subepithelial fibrosis has been reported in all severities of asthma (5, 17) as well as in subjects with atopic rhinitis (23, 24), and even in children with difficult-to-treat asthma (25, 26). The subepithelial fibrosis occurs in the lamina reticularis layer just below the basement membrane, which leads to thickening of the basement membrane just underneath the epithelium. Fibrosis is a result of increased deposition of extracellular matrix (ECM) proteins, including collagens I, III, and V; fibronectin; tenascin; lumican; and biglycan (4, 27–30) by fibroblasts. Some variable correlations have been found between the severity of asthma, airway hyperresponsiveness or attack score, and subepithelial collagen types I and III deposition in the airways (31–34). Subepithelial fibrosis has been associated with the severity of asthma, and in severe asthma, increased airway wall thickness is observed (35). Proteoglycan deposition in the ECM and bronchial fibroblast production of proteoglycans also correlate with airway responsiveness in subjects with asthma (27, 36). An imbalance between ECM proteins production and degradation has also been found in asthmatic airways. The level of proteases and antiproteases may favor a profibrotic balance. Interstitial cells, macrophages, and neutrophils are the major sources of proteases and antiproteases. Matrix metalloproteinases (MMPs) are a family of proteases implicated in collagen degradation. MMP-2, MMP-3, MMP-8, and MMP-9 are the MMPs related to asthma (37–40). Among these, MMP-9 levels are reported to be significantly higher in the sputum of patients with asthma compared with control subjects (39). MMPs are implicated in airway inflammation through their influence on eosinophil trafficking (41) and in airway remodeling, not only by matrix reorganization but also by its effects on angiogenesis (42) and smooth muscle hyperplasia (43, 44). Elevated sputum
302
PROCEEDINGS OF THE AMERICAN THORACIC SOCIETY VOL 6
2009
Figure 1. Main characteristics of airway remodeling. Airway remodeling refers to structural changes in airways of individuals with asthma; these changes include (1) epithelial alteration, (2) subepithelial fibrosis, (3) increased smooth muscle mass, (4) goblet and mucous gland hyperplasia, (5) angiogenesis, (6) loss of cartilage integrity, and (7) inflammation.
MMP-9 levels are associated with a fall in FEV1 after allergen challenge and are linked to asthma severity (41, 45). Bronchoalveolar lavage level of MMP-8 inversely correlates with FEV1 in patients with asthma (38). It has also been proposed that the remodeling process might be beneficial in airway diseases. Lambert and colleagues (46) have suggested that airway wall thickening may protect against bronchoconstriction. Collagen deposition in subepithelial matrix may inhibit narrowing by making the airway wall stiffer, representing an additional load on airway smooth muscle (24). Hyaluronan and versican deposition in and around the smooth muscle also counteracts airway narrowing and smooth muscle shortening. Experiments conducted on rat models of allergeninduced asthma suggested that airway responsiveness may increase after airway inflammation, but may decrease with airway deposition of fibronectin and collagen (47).
INCREASED SMOOTH MUSCLE MASS Respiratory airway smooth muscle is the critical effector cell modulating airway tone. In asthmatic airways the smooth muscle mass is increased due to coordinated increase in size (hypertrophy) and number (hyperplasia) of airway smooth muscle cells. Importantly, the asthmatic smooth muscle cells take on not only the secretory and proliferative phenotype, but can also migrate to the subepithelial area of the asthmatic airways (6, 48, 49). Smooth muscle cells are known to actively participate in the inflammatory and remodeling processes though their release of proinflammatory cytokines, chemokines, and ECM proteins (50–52), and may therefore contribute to the pathogenesis of asthma. Migration of smooth muscle cells is a recently described feature of airway remodeling. We have shown that chemokines have the ability to induce human airway smooth muscle cell migration and to increase their contractility
Figure 2. (A) Endobronchial biopsy stained with hematoxylin and eosin of a subject with asthma showing goblet (G) cell hyperplasia. (B) Endobronchial biopsy stained with hematoxylin and eosin of a subject with asthma showing extensive total subepithelial fibrosis (F) and increased smooth muscle (SMC) mass. (C) Lung biopsy showing a small airway from a subject with asthma showing increased smooth muscle mass and submucosal fibrosis. Reprinted by permission from Reference 65.
in vitro, implementing another avenue which may significantly contribute to the overall airflow obstruction in these patients (49). The importance of smooth muscle mass has been correlated to asthma severity (53).
GOBLET AND MUCOUS GLAND HYPERPLASIA Goblet cells hyperplasia and submucosal gland hyperplasia are seen in asthmatic airways of both adults and children; it is a feature particularly evident in fatal asthma (6, 7, 26). Functional consequences of these abnormalities mostly refer to increased
Bergeron, Al-Ramli, and Hamid: Remodeling in Asthma
sputum production, airway narrowing from sputum secretion, and increased airway wall thickness (6).
ANGIOGENESIS Vascular alterations include increased size of airway wall vessels and angiogenesis (9). Changes in the airway wall microvasculature can contribute to airway wall edema and result from angiogenesis. Increased airway vascularity is seen in asthma (9, 10) in association with a greater expression of the vascular endothelial growth factor (VEGF) (54). Clinical consequences of airway wall angiogenesis are reduced airway caliber via airway wall edema, and increased inflammatory and remodeling mediators delivery into the airway wall having subsequent influence on structural and inflammatory cells.
LOSS OF CARTILAGE INTEGRITY Cartilage is an important determinant of airway wall stiffness and integrity. Decreased cartilage volume and increased cartilage proteoglycan degradation are seen in asthmatic airways (8). Reduced cartilage integrity may result in a more powerful bronchoconstriction from airway smooth muscle bundles load reduction. Cartilage degradation can contribute to chronic airway obstruction, and allow more powerful bronchoconstriction for a given degree of airway smooth muscle contraction (55).
INFLAMMATION Inflammation is another component of airway remodeling. There is good evidence that asthma is a heterogeneous disease. Airways of individuals with mild and moderate asthma are characterized by a Th2 profile inflammation, in which there is an overabundance of eosinophils, mast cells, and Th2 lymphocytes. These inflammatory cells release mediators which then trigger bronchoconstriction, mucus secretion, and, possibly, remodeling. The number of infiltrating leukocytes such as mast cells, eosinophils, and CD81 and CD451 T cells correlates with airway hyperresponsiveness in patients treated with inhaled corticosteroids (ICS) (56). The inflammatory mediators that drive this process include Th2 cytokines (IL-4, IL-5, IL-9, and IL-13), transforming growth factor (TGF)-b, granulocyte/macrophagecolony stimulating factor (GM-CSF), lipid mediators, and histamine. Some of these mediators have potent remodeling properties, such as TGF-b, IL-11, and IL-17 (31, 57, 58). Recently, a new subtype of T cells has been implicated in the pathogenesis of asthma, particularly in severe asthma, where the importance of noneosinophilic or neutrophilic inflammation is well described. This subtype of T cells are called Th-17, which secrete IL-17 A and F and might be involved in airway remodeling.
TOOLS USED TO MEASURE AIRWAY REMODELING Airway remodeling is clinically defined as persistent airflow obstruction despite aggressive antiinflammatory therapies. The standard assessment of remodeling is obtained by surgical lung specimen or airway tissues sampled through flexible bronchoscopy. Flexible bronchoscopy is a minimally invasive technique, but requires specialist expertise; tools have been developed to bypass the biopsy sampling. Among these tools, indirect analysis of blood, urine, or sputum remodeling markers have been developed. However, we can only gain an insight into the ongoing fibrotic process, and we do not know if the fluid variations in remodeling markers have significant consequences in the diseased airway walls. Other alternative tools, including high-resolution computed tomography, endobronchial ultra-
303
sounds, and lung function measurement can also be used as screening tools, but modulation of airway remodeling will need to be confirmed on airway wall specimen. Clinicians should consider airway remodeling in all subjects with asthma and rhinitis. Fixed airflow obstruction is regarded as a late and irreversible manifestation of airway remodeling. For this reason, even without good and easily available tools to confirm the presence of remodeling, clinicians should use controlling medications to prevent development or worsening of airway and tissue remodeling.
REMODELING IN ALLERGIC DISEASES IS NOT RESTRICTED TO THE AIRWAYS Allergen exposure triggers in sensitized subjects an inflammatory response that will be expressed in the targeted organ, such as the nasal mucosa, the skin, and the airway mucosa. Allergic rhinitis, atopic dermatitis, and asthma share many pathologic features. In fact, the same profile of inflammation, mediators, and adhesion molecules are observed in upper and lower allergic airway diseases as well as skin allergic disease. There is a common cellular inflammation pattern characterized by eosinophil, mast cell, and CD41 T cell influx (59, 60). Mediators, including histamine, cysteinyl-leukotrienes, interleukin (IL)-4, IL-5, IL-13, RANTES, and eotaxin are expressed in both upper and lower airways (61, 62). Although initial inflammation induced by allergens is similar in upper and lower airways, long-term structural consequences differ. In allergic rhinitis, minimal epithelial shedding is observed with less subsequent degree of basement membrane thickening (reviewed in Reference 63). Atopic dermatitis is also characterized by remodeling with increased expression of profibrotic cytokines (including TGF-b, IL-11, and IL-17) and increased subepithelial deposition of collagen (64). Remodeling is observed in all atopic diseases, which reinforces the hypothesis that remodeling is an inflammatory driven process.
CONCLUSIONS The features of airway remodeling include subepithelial fibrosis, elevated numbers and volume of mucous cells in the epithelium, increased amounts of airway smooth muscle, and increased vascularization of the airway wall. It is important to understand the etiology of airway remodeling in asthma to develop therapies that inhibit or reverse it. The concern that asthma is associated with airway remodeling and loss of pulmonary function prompts clinicians to consider early recognition and early intervention. Currently, antiinflammatory drugs, including steroids, form the basis of asthma therapy. However, their effects on remodeling and chronic structural changes in the airways remains to be elucidated. It is for this reason that new treatments should be directed not only against inflammation itself but also against these chronic changes in the asthmatic lungs. Conflict of Interest Statement: None of the authors has a financial relationship with a commercial entity that has an interest in the subject of this manusript.
References 1. Redington AE, Howarth PH. Airway wall remodelling in asthma. Thorax 1997;52:310–312. 2. James AL, Maxwell PS, Pearce-Pinto G, Elliot JG, Carroll NG. The relationship of reticular basement membrane thickness to airway wall remodeling in asthma. Am J Respir Crit Care Med 2002;166:1590–1595. 3. Naylor B. The shedding of the mucosa of the bronchial tree in asthma. Thorax 1962;17:69–72. 4. Roche WR, Beasley R, Williams JH, Holgate ST. Subepithelial fibrosis in the bronchi of asthmatics. Lancet 1989;1:520–524.
304 5. Elias JA, Zhu Z, Chupp G, Homer RJ. Airway remodeling in asthma. J Clin Invest 1999;104:1001–1006. 6. Carroll N, Elliot J, Morton A, James A. The structure of large and small airways in nonfatal and fatal asthma. Am Rev Respir Dis 1993;147: 405–410. 7. Aikawa T, Shimura S, Sasaki H, Ebina M, Takishima T. Marked goblet cell hyperplasia with mucus accumulation in the airways of patients who died of severe acute asthma attack. Chest 1992;101:916–921. 8. Haraguchi M, Shimura S, Shirato K. Morphometric analysis of bronchial cartilage in chronic obstructive pulmonary disease and bronchial asthma. Am J Respir Crit Care Med 1999;159:1005–1013. 9. Li X, Wilson JW. Increased vascularity of the bronchial mucosa in mild asthma. Am J Respir Crit Care Med 1997;156:229–233. 10. Tanaka H, Yamada G, Saikai T, Hashimoto M, Tanaka S, Suzuki K, Fujii M, Takahashi H, Abe S. Increased airway vascularity in newly diagnosed asthma using a high-magnification bronchovideoscope. Am J Respir Crit Care Med 2003;168:1495–1499. 11. Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev 1997;77: 1033–1079. 12. Kroegel C, Virchow JC Jr, Luttmann W, Walker C, Warner JA. Pulmonary immune cells in health and disease: the eosinophil leucocyte (Part I). Eur Respir J 1994;7:519–543. 13. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone: I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:2348–2357. 14. Le Gros G, Ben-Sasson SZ, Seder R, Finkelman FD, Paul WE. Generation of interleukin 4 (IL-4)-producing cells in vivo and in vitro: IL-2 and IL-4 are required for in vitro generation of IL-4producing cells. J Exp Med 1990;172:921–929. 15. Swain SL, Weinberg AD, English M, Huston G. IL-4 directs the development of Th2-like helper effectors. J Immunol 1990;145: 3796–3806. 16. Zeiger RS, Dawson C, Weiss S. Relationships between duration of asthma and asthma severity among children in the Childhood Asthma Management Program (CAMP). J Allergy Clin Immunol 1999;103: 376–387. 17. Boulet LP, Laviolette M, Turcotte H, Cartier A, Dugas M, Malo JL, Boutet M. Bronchial subepithelial fibrosis correlates with airway responsiveness to methacholine. Chest 1997;112:45–52. 18. Laitinen LA, Heino M, Laitinen A, Kava T, Haahtela T. Damage of the airway epithelium and bronchial reactivity in patients with asthma. Am Rev Respir Dis 1985;131:599–606. 19. Montefort S, Roberts JA, Beasley R, Holgate ST, Roche WR. The site of disruption of the bronchial epithelium in asthmatic and nonasthmatic subjects. Thorax 1992;47:499–503. 20. Ordonez C, Ferrando R, Hyde DM, Wong HH, Fahy JV. Epithelial desquamation in asthma: artifact or pathology? Am J Respir Crit Care Med 2000;162:2324–2329. 21. Boulet LP, Turcotte H, Carrier G, Boutet M, Laviolette M. Increased maximal airway response to methacholine during seasonal allergic rhinitis in nonasthmatic subjects: relationships with airway wall thickness and inflammation. Eur Respir J 1995;8:913–921. 22. Jeffery PK, Wardlaw AJ, Nelson FC, Collins JV, Kay AB. Bronchial biopsies in asthma. An ultrastructural, quantitative study and correlation with hyperreactivity. Am Rev Respir Dis 1989;140:1745–1753. 23. Chakir J, Laviolette M, Boutet M, Laliberte R, Dube J, Boulet LP. Lower airways remodeling in nonasthmatic subjects with allergic rhinitis. Lab Invest 1996;75:735–744. 24. Milanese M, Crimi E, Scordamaglia A, Riccio A, Pellegrino R, Canonica GW, Brusasco V. On the functional consequences of bronchial basement membrane thickening. J Appl Physiol 2001;91:1035–1040. 25. Payne DN, Rogers AV, Adelroth E, Bandi V, Guntupalli KK, Bush A, Jeffery PK. Early thickening of the reticular basement membrane in children with difficult asthma. Am J Respir Crit Care Med 2003;167: 78–82. 26. Jenkins HA, Cool C, Szefler SJ, Covar R, Brugman S, Gelfand EW, Spahn JD. Histopathology of severe childhood asthma: a case series. Chest 2003;124:32–41. 27. Huang J, Olivenstein R, Taha R, Hamid Q, Ludwig M. Enhanced proteoglycan deposition in the airway wall of atopic asthmatics. Am J Respir Crit Care Med 1999;160:725–729. 28. Laitinen A, Altraja A, Kampe M, Linden M, Virtanen I, Laitinen LA. Tenascin is increased in airway basement membrane of asthmatics and decreased by an inhaled steroid. Am J Respir Crit Care Med 1997; 156:951–958.
PROCEEDINGS OF THE AMERICAN THORACIC SOCIETY VOL 6
2009
29. Wilson JW, Li X. The measurement of reticular basement membrane and submucosal collagen in the asthmatic airway. Clin Exp Allergy 1997;27:363–371. 30. Karjalainen EM, Lindqvist A, Laitinen LA, Kava T, Altraja A, Halme M, Laitinen A. Airway inflammation and basement membrane tenascin in newly diagnosed atopic and nonatopic asthma. Respir Med 2003;97:1045–1051. 31. Minshall E, Chakir J, Laviolette M, Molet S, Zhu Z, Olivenstein R, Elias JA, Hamid Q. IL-11 expression is increased in severe asthma: association with epithelial cells and eosinophils. J Allergy Clin Immunol 2000;105:232–238. 32. Hoshino M, Nakamura Y, Sim JJ. Expression of growth factors and remodelling of the airway wall in bronchial asthma. Thorax 1998;53: 21–27. 33. Chetta A, Foresi A, Del Donno M, Bertorelli G, Pesci A, Olivieri D. Airways remodeling is a distinctive feature of asthma and is related to severity of disease. Chest 1997;111:852–857. 34. Chu HW, Halliday JL, Martin RJ, Leung DY, Szefler SJ, Wenzel SE. Collagen deposition in large airways may not differentiate severe asthma from milder forms of the disease. Am J Respir Crit Care Med 1998;158:1936–1944. 35. Little SA, Sproule MW, Cowan MD, Macleod KJ, Robertson M, Love JG, Chalmers GW, McSharry CP, Thomson NC. High resolution computed tomographic assessment of airway wall thickness in chronic asthma: reproducibility and relationship with lung function and severity. Thorax 2002;57:247–253. 36. Westergren-Thorsson G, Chakir J, Lafreniere-Allard MJ, Boulet LP, Tremblay GM. Correlation between airway responsiveness and proteoglycan production by bronchial fibroblasts from normal and asthmatic subjects. Int J Biochem Cell Biol 2002;34:1256–1267. 37. Lemjabbar H, Gosset P, Lamblin C, Tillie I, Hartmann D, Wallaert B, Tonnel AB, Lafuma C. Contribution of 92 kDa gelatinase/type IV collagenase in bronchial inflammation during status asthmaticus. Am J Respir Crit Care Med 1999;159:1298–1307. 38. Prikk K, Maisi P, Pirila E, Reintam MA, Salo T, Sorsa T, Sepper R. Airway obstruction correlates with collagenase-2 (MMP-8) expression and activation in bronchial asthma. Lab Invest 2002;82:1535– 1545. 39. Vignola AM, Riccobono L, Mirabella A, Profita M, Chanez P, Bellia V, Mautino G, D’accardi P, Bousquet J, Bonsignore G. Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. Am J Respir Crit Care Med 1998;158:1945–1950. 40. Suzuki R, Kato T, Miyazaki Y, Iwata M, Noda Y, Takagi K, Nakashima N, Torii K. Matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in sputum from patients with bronchial asthma. J Asthma 2001;38:477–484. 41. Wenzel SE, Balzar S, Cundall M, Chu HW. Subepithelial basement membrane immunoreactivity for matrix metalloproteinase 9: association with asthma severity, neutrophilic inflammation, and wound repair. J Allergy Clin Immunol 2003;111:1345–1352. 42. Johnson C, Sung HJ, Lessner SM, Fini ME, Galis ZS. Matrix metalloproteinase-9 is required for adequate angiogenic revascularization of ischemic tissues: potential role in capillary branching. Circ Res 2003;94:262–268. 43. Johnson C, Galis ZS. Matrix metalloproteinase-2 and -9 differentially regulate smooth muscle cell migration and cell-mediated collagen organization. Arterioscler Thromb Vasc Biol 2003;24:54–60. 44. Johnson S, Knox A. Autocrine production of matrix metalloproteinase-2 is required for human airway smooth muscle proliferation. Am J Physiol 1999;277:L1109–L1117. 45. Cataldo DD, Bettiol J, Noel A, Bartsch P, Foidart JM, Louis R. Matrix metalloproteinase-9, but not tissue inhibitor of matrix metalloproteinase-1, increases in the sputum from allergic asthmatic patients after allergen challenge. Chest 2002;122:1553–1559. 46. Lambert RK, Codd SL, Alley MR, Pack RJ. Physical determinants of bronchial mucosal folding. J Appl Physiol 1994;77:1206–1216. 47. Palmans E, Kips JC, Pauwels RA. Prolonged allergen exposure induces structural airway changes in sensitized rats. Am J Respir Crit Care Med 2000;161:627–635. 48. Johnson PR, Burgess JK. Airway smooth muscle and fibroblasts in the pathogenesis of asthma. Curr Allergy Asthma Rep 2004;4:102–108. 49. Joubert P, Lajoie-Kadoch S, Labonte I, Gounni AS, Maghni K, Wellemans V, Chakir J, Laviolette M, Hamid Q, Lamkhioued B. CCR3 expression and function in asthmatic airway smooth muscle cells. J Immunol 2005;175:2702–2708.
Bergeron, Al-Ramli, and Hamid: Remodeling in Asthma 50. Panettieri RA Jr. Airway smooth muscle: an immunomodulatory cell. J Allergy Clin Immunol 2002;110:S269–S274. 51. Hakonarson H, Maskeri N, Carter C, Grunstein MM. Regulation of TH1- and TH2-type cytokine expression and action in atopic asthmatic sensitized airway smooth muscle. J Clin Invest 1999;103:1077– 1087. 52. Johnson PR. Role of human airway smooth muscle in altered extracellular matrix production in asthma. Clin Exp Pharmacol Physiol 2001; 28:233–236. 53. Benayoun L, Druilhe A, Dombret MC, Aubier M, Pretolani M. Airway structural alterations selectively associated with severe asthma. Am J Respir Crit Care Med 2003;167:1360–1368. 54. Hoshino M, Takahashi M, Aoike N. Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis. J Allergy Clin Immunol 2001;107:295–301. 55. Noble PB, Turner DJ, Mitchell HW. Relationship of airway narrowing, compliance, and cartilage in isolated bronchial segments. J Appl Physiol 2002;92:1119–1124. 56. Sont JK, Han J, van Krieken JM, Evertse CE, Hooijer R, Willems LN, Sterk PJ. Relationship between the inflammatory infiltrate in bronchial biopsy specimens and clinical severity of asthma in patients treated with inhaled steroids. Thorax 1996;51:496–502. 57. Molet S, Hamid Q, Davoine F, Nutku E, Taha R, Page´ N, Olivenstein R, Elias J, Chakir J. IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J Allergy Clin Immunol 2001;108:430–438. 58. Chakir J, Shannon J, Molet S, Fukakusa M, Elias J, Laviolette M, Boulet LP, Hamid Q. Airway remodeling-associated mediators in moderate to severe asthma: effect of steroids on TGF-beta, IL-11, IL-17, and
305
59.
60.
61.
62.
63.
64.
65.
type I and type III collagen expression. J Allergy Clin Immunol 2003; 111:1293–1298. Bradley BL, Azzawi M, Jacobson M, Assoufi B, Collins JV, Irani AM, Schwartz LB, Durham SR, Jeffery PK, Kay AB. Eosinophils, Tlymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy specimens from atopic subjects with asthma: comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsiveness. J Allergy Clin Immunol 1991;88:661–674. Varga EM, Jacobson MR, Till SJ, Masuyama K, O’Brien F, Rak S, Lund V, Scadding GK, Hamid QA, Durham SR. Cellular infiltration and cytokine mRNA expression in perennial allergic rhinitis. Allergy 1999; 54:338–345. KleinJan A, Dijkstra MD, Boks SS, Severijnen LA, Mulder PG, Fokkens WJ. Increase in IL-8, IL-10, IL-13, and RANTES mRNA levels (in situ hybridization) in the nasal mucosa after nasal allergen provocation. J Allergy Clin Immunol 1999;103:441–450. Nag S, Lamkhioued B, Renzi PM. Interleukin-2-induced increased airway responsiveness and lung Th2 cytokine expression occur after antigen challenge through the leukotriene pathway. Am J Respir Crit Care Med 2002;165:1540–1545. Bousquet J, Jacquot W, Vignola AM, Bachert C, Van Cauwenberge P. Allergic rhinitis: a disease remodeling the upper airways? J Allergy Clin Immunol 2004;113:43–49. Toda M, Leung DY, Molet S, Boguniewicz M, Taha R, Christodoulopoulos P, Fukuda T, Elias JA, Hamid QA. Polarized in vivo expression of IL-11 and IL-17 between acute and chronic skin lesions. J Allergy Clin Immunol 2003;111:875–881. Joubert P, Hamid Q. Role of airway smooth muscle in airway remodeling. J Allergy Clin Immunol 2005;116:713–716.
